Roxana Mehran, MD, FACC, FACP, FCCP, FESC, FAHA, FSCAI is an American physician who is an internationally renowned influencer in the field of interventional cardiovascular disease. Throughout her career as an academician, clinician, and researcher she has achieved the highest levels of recognition for her knowledge, expertise, and accomplishments within the field. Dr. Mehran is currently Professor of Medicine, Cardiology and Professor of Population Health Science and Policy at the Icahn School of Medicine at Mount Sinai in New York. She is also Director of Interventional Cardiovascular Research and Clinical Trials at The Zena and Michael A. Weiner Cardiovascular Institute at Mount Sinai Hospital where, over the past five years, she has led the development of a globally-respected data and clinical coordination center to support large, multicenter, multinational clinical trials designed, by her team, to help clinicians improve outcomes and quality of life for patients undergoing interventional cardiovascular procedures. In recent years, her work has had a special emphasis on gaining a deeper understanding of anticoagulation and antiplatelet regimens post angioplasty and transcatheter valve replacement; and collection and interpretation of sex-specific data in cardiovascular clinical trials. Dr. Mehran is sought after for her twenty years of experience in collaborating with regulatory agencies, including the Food and Drug Administration (FDA), to design and conduct clinical trials that help to shape health policy, and clinical standards and guidelines. She is a widely published author with greater than 600 original abstracts, 20 book chapters, and more than 700 peer-reviewed papers, published in the most prestigious journals, including the New England Journal of Medicine, with a focus in the areas of atherosclerosis; contrast-induced nephropathy; gender disparities, in-stent restenosis; dual antiplatelet therapy (DAPT); percutaneous coronary intervention (PCI); and drug-eluting stents (PCI). In addition to her publications, Dr. Mehran has developed several risk scores for bleeding and acute kidney injury to identify patients at risk for these complications.
In recognition of her work, Dr. Mehran has been the recipient of numerous prestigious awards and special acknowledgements including recognition in “The World’s Most Influential Scientific Minds 2014”, The IP and Science, Thomson Reuters; the Elite Service and Scholarship Award of the Journal of the American College of Cardiology (JACC) 2013; the Elite Reviewer Award for Catheterization and Cardiovascular Interventions 2013 (CCI); the F. Mason Sones Jr, MD Distinguished Service Award at the 36th Annual Society of Cardiac Angiography and Interventions (SCAI) 2013; National Aeronautics and Space Administration ISC Group Achievement Award for Sex and Gender Report Team for outstanding contributions to “Impact of Sex and Gender on Adaption to Spaceflight” report; and she is consistently names amongst NY’s Best Doctors. She has received fellowship appointments to a number of the most prestigious organizations governing the field including the American Heart Association (AHA) and the American College of Cardiology (ACC) where she also is a member of the writing committee for the ACC/AHA PCI guidelines; and SCAI where she serves on the board of trustees, and for whom she has been named 2016 Program Chair for its annual scientific sessions, having served as co-chair for the 2014 and 2015 programs. Dr. Mehran has co-founded a number of important initiatives including the Academic Research Consortium (ARC) which is responsible for writing definition papers for standardized bleeding definitions for cardiovascular clinical trials (BARC) and standardized endpoint definitions for transcatheter valve replacement (VARC); Women in Innovation (WIN) which expanded into two important nationally recognized programs: WIN-TAVI and SCAI-WIN; and she is a founding physician of the Cardiovascular Research Foundation (CRF) in New York where she developed, and was responsible for the growth of, its internationally respected data coordinating center, and where she currently holds the position of Chief Scientific Officer.
Since 1995, Dr. Mehran has been involved with more than 125 clinical research studies worldwide. Many of those studies have led to the establishment of practice parameters for physicians, and continue to influence clinical decision making today. She has sat on nineteen editorial boards at some of the most prestigious and influential journals including JACC; Circulation; Circulation Research; the American Heart Journal, and the Journal of Clinical and Invasive Cardiology (CCI), to name a few. She has been invited to lead or participate in more than forty important committees including executive and steering committees for some of the most relevant clinical trials in the field; councils and guideline writing committees of the ACC and AHA including as a co-author of the PCI and DAPT guidelines. She has been invited to participate in numerous physician advisory boards and boards of directors. She has been granted greater than 20 faculty appointments at important national and international scientific conferences where she is regularly invited to present on late-breaking and other important scientific data. Dr. Mehran currently sits on the writing committee for appropriate use criteria for diagnostic catheterizations and valvular heart disease. She is a member of the ACC’s NDCR CATH-PCI Registry steering committee. She is incoming Chair of the Interventional Council of the ACC; and she is the global principle investigator (PI), and a member of several data safety monitoring boards (DSMB), for a number of large prospective global studies. She is a board member for the nonprofit Harboring Hearts in New York City, and is the Medical Director of the Health Disparities Research Consortium (HDRC).
Throughout her groundbreaking career, Dr. Mehran has mentored, and continues to support the careers of, countless numbers of medical students, residents, fellows-in-training, and peers.
Prior to her current position at Mount Sinai, Dr. Mehran held academic, clinical, and research appointments at Columbia University Medical Center in New York, and at the Washington Hospital Center in Washington, DC. She completed her training in internal medicine at the University of Connecticut, where she also served as Chief Medical Resident, before completing fellowships in both cardiovascular disease and interventional cardiology at Mount Sinai Medical Center.